Interview with Pavel Chistyakov, General Manager, Pierre Fabre Russia
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
Address: 119435 г.Москва, Саввинская набережная, д. 11,Russia
Tel: +7 (495) 789 9533
Web: http://www.pierre-fabre-Russia.ru/
Today, almost half a century since its founding, the Pierre Fabre Group is the second largest private pharmaceutical company in France and has market presence in over 140 countries around the world. Business within the company’s Russian affiliate is beginning to evolve rapidly. In 1993, the first drug produced by Pierre Fabre appeared on the Russian market. In 1999, the Group began selling skin care products through its exclusive distributor. In 2008, the decision was made to merge all areas in Russia, and in 2009, the company opened a 100% Russian subsidiary. In May 2009, the first skin care products were delivered to the affiliate from France, and in 2010, the first dental products were delivered.
In Russia, the main activity of LLC Pierre Fabre is the promotion of skin cosmetics, which are divided in two areas: dermatology and aesthetic skin care.
Pierre Fabre’s skin care products are sold exclusively in pharmacies.
Dermo-cosmetics and pharmaceutical products
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here
